ADAMS ADRIAN 4

What Happened Adrian Adams, a director of Akebia Therapeutics (AKBA), received two awards on June 17, 2026: 35,700 restricted stock units (RSUs) and a derivative award in the form of a stock option covering 53,600 shares. Both grants are reported at $0.00 (standard for compensation grants), for a combined potential of 89,300 shares. These are awards/compensation — not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-17; Report filed: 2026-06-22 (appears to be filed after the typical 2-business-day Form 4 deadline).
• Grants: 35,700 RSUs @ $0.00; 53,600-share stock option (derivative) @ $0.00.
• Vesting: Both awards vest 100% on the first anniversary of the grant (or immediately prior to the first annual meeting if earlier), subject to continuous service (per footnotes/F1 and F2).
• Plan and program: Awards granted under the Issuer’s 2023 Stock Incentive Plan and the Fifth Amended and Restated Non‑Employee Director Compensation Program.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Reported five calendar days after the grants; appears late versus the usual 2-business-day Form 4 requirement (late filings reduce timely transparency).

Context RSUs convert to shares when they vest; the stock option is a grant giving the right to buy shares in the future if exercised (this filing documents the grant, not an exercise or sale). Director awards are common as part of non-employee director compensation and do not by themselves indicate a buy or sell decision in the market.